TOPLINE:

A low-dose peanut oral immunotherapy (OIT) protocol using parent-measured dosing can desensitize children aged 1-4 years with peanut allergy. The approach appears to be acceptably safe and may yield greater improvements in quality of life than peanut avoidance, researchers reported.

METHODOLOGY:

Investigators conducted a randomized trial that included 54 children with confirmed or highly probable peanut allergy at a tertiary pediatric hospital in Western Australia to compare peanut OIT with peanut avoidance.

Participants in the peanut OIT group received 1-360 mg of peanut protein in the form of defatted peanut flour sold as powdered peanut butter.

At 12 months, researchers assessed how many participants in the OIT and avoidance groups could tolerate > 600 mg peanut protein du

See Full Page